Ieq Capital LLC Purchases 35,378 Shares of IQVIA Holdings Inc. $IQV

Ieq Capital LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 152,375 shares of the medical research company’s stock after acquiring an additional 35,378 shares during the period. Ieq Capital LLC owned about 0.09% of IQVIA worth $34,347,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA during the 4th quarter worth about $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA during the 3rd quarter worth about $30,000. Finally, Activest Wealth Management increased its position in shares of IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Price Performance

Shares of IQV stock opened at $181.10 on Friday. The stock’s fifty day moving average is $173.56 and its 200-day moving average is $193.68. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a market capitalization of $30.23 billion, a PE ratio of 22.44, a PEG ratio of 1.55 and a beta of 1.21. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IQV. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Morgan Stanley set a $225.00 target price on IQVIA in a report on Thursday, May 7th. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 6th. Finally, Truist Financial decreased their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and a consensus price target of $224.13.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.